AEterna Zentaris gets market approval in Japan for Cetrotide in-vitro fertilization treatment

By Elaine Rigoli

Tampa, Fla., April 20 - AEterna Zentaris Inc. said it has gained market approval for Cetrotide (cetrorelix) in Japan for in-vitro fertilization.

Cetrotide (cetrorelix) will be manufactured and marketed in Japan by partners Nippon Kayaku Co., Ltd. and Shionogi & Co., Ltd.

AEterna Zentaris received an undisclosed milestone payment from its partners and will receive revenues from the supply of Cetrotide to its Japanese partners, according to a news release.

Cetrotide, expected to be launched in Japan before 2007, has been marketed worldwide, excluding Japan, by Serono SA since 1999, providing AEterna Zentaris with annual revenues of over $20 million, the company said.

Cetrotide is a luteinizing hormone-releasing hormone antagonist treatment approved for in-vitro fertilization.

AEterna Zentaris is a Quebec City, Quebec-based biopharmaceutical company focused on oncology and endocrine therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.